Therapies for Treatment-Resistant Depression

I am Associate Professor with Tenure of Psychiatry and Neuroscience, and Director of the Depression and Anxiety Center for Discovery and Treatment (DAC) at the Icahn School of Medicine at Mount Sinai (ISMMS). My program of research utilizes molecular, neuroimaging, and experimental therapeutics approaches aimed at elucidating the fundamental mechanisms underlying stress-related disorders in humans, including major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and anxiety disorders. The overall goal of my research is to advance the treatment of stress-related disorders through an enhanced understanding of disease pathogenesis and therapeutic mechanisms of action. Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

1. Introduction 2. Treatment-Resistant Depression: Epidemiology and Clinical Presentation 3. Molecular Neuropharmacology of Treatment-Resistant Depression 4. Neurobiology and Neuroimaging of Treatment-Resistant Depression 5. Pharmacotherapy of Treatment-Resistant Depression: Overview and Look Ahead 6. Lithium, Dopamine Modulators, and Other Augmentation Strategies for Treatment-Resistant Depression 7. Ketamine and Esketamine for Treatment-Resistant Depression 8. The Impact of Inflammation on Treatment Resistance in Depression: Mechanisms and Translational Opportunities 9. Novel Pharmacotherapies for Treatment-Resistant Depression: A Focus on Glutamate and GABA Modulators 10. Electroconvulsive Therapy for Treatment-Resistant Depression 11. Transcranial Magnetic Stimulation for Treatment-Resistant Depression 12. Vagal Nerve Stimulation for Treatment-Resistant Depression 13. Deep Brain Stimulation for Treatment-Resistant Depression 14. Psilocybin and Other Psychedelic Agents in Development for Treatment-Resistant Depression 15. Neuroimaging Biomarkers in Treatment Selection for Treatment-Resistant Depression 16. The Role of Genetics in Treatment-Resistant Depression